---
title: "B7-H3 Antibody–Drug Conjugate Turning Immune Evasion Into Vulnerability"
id: "the-lancet-oncology-6-b7-h3-antibody-drug-conjugate-turning-immune-evasion-into-vulnerability"
canonical_url: "https://medichelpline.com/clinical-feed/the-lancet-oncology-6-b7-h3-antibody-drug-conjugate-turning-immune-evasion-into-vulnerability"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "The Lancet Oncology"
source_url: "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00005-7/fulltext?rss=yes"
doi: "10.1016/S1470-2045(26)00005-7"
published_at: "2026-04-01T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# B7-H3 Antibody–Drug Conjugate Turning Immune Evasion Into Vulnerability
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/the-lancet-oncology-6-b7-h3-antibody-drug-conjugate-turning-immune-evasion-into-vulnerability
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** The Lancet Oncology
- **Source URL:** [Original Journal Publication](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00005-7/fulltext?rss=yes)
- **DOI:** [10.1016/S1470-2045(26)00005-7](https://doi.org/10.1016%2FS1470-2045(26)00005-7)
- **Published At:** 2026-04-01T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy in several indications owing to their favourable balance between efficacy and tolerability. Trastuzumab deruxtecan exemplifies this paradigm shift, having achieved regulatory approvals across multiple HER2 (ERBB2)-expressing or HER2-mutated solid tumours, including breast, gastric, and non-small-cell lung cancers (NSCLCs).
## Clinical Analysis & Structured Key Points
The Lancet Oncology published a clinical update in Oncology on 01 Apr 2026. The item focuses on B7-H3 antibody–drug conjugate turning immune evasion into vulnerability. Review the original article for the full source wording and details.
## Related Clinical Research

- [Antibody-Drug Conjugates for Advanced Esophageal Cancer: Targets, Evidence, and Clinical Integrati](https://medichelpline.com/clinical-feed/pubmed-42700288.md) (DOI: 10.1007/s11864-026-01411-2)
- [Stepwise Molecular Profiling Reveals Co-occurring EGFR L858R and HER2 Amplification in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42681853.md) (DOI: 10.12659/AJCR.953829)
- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)
- [Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, organ patterns and management](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-clinical-toxicity-of-adcs-and-ici-adc-combinations-mechanisms-patterns-and.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.